Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals Inc. (LIPO)
Company Research
Source: GlobeNewswire
PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine; and Pradeep Tyagi, PhD, MBA, Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Drs. Hafron and Tyagi have complementing expertise in both clinical and translational research in cancer treatment, with a focus on urologic oncology. Dr. Michael Chancellor, M.D., Chief Medical Officer of Lipella, stated, “I look forward to working with Dr. Hafron and Dr. Tyagi in the advancement of our discovery efforts in the treatment of non-muscle invasive bladder cancer (NMIBC), a disease that affects nearly one million
Show less
Read more
Impact Snapshot
Event Time:
LIPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIPO alerts
High impacting Lipella Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
LIPO
News
- Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) is now covered by analysts at Maxim Group. They set a "buy" rating and a $2.00 price target on the stock.MarketBeat
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024GlobeNewswire
LIPO
Sec Filings
- 5/15/24 - Form 4
- 5/9/24 - Form 10-Q
- 5/6/24 - Form SC
- LIPO's page on the SEC website